UZEDY® Q1 2026 Sales Surge by 62%

Medincell and its partner Teva Pharmaceuticals announced impressive financial results for UZEDY®. In the first quarter of 2026, U.S. net sales for UZEDY® reached $63 million, marking a significant 62% increase compared to the same period in 2025. This product, a long-acting injectable formulation of risperidone, has seen continued growth since its FDA approval in April 2023 for schizophrenia and later for Bipolar I Disorder in October 2025.

Medincell benefits from mid- to high-single-digit royalties on these sales, with potential commercial milestone payments up to $105 million. An additional promising development is the FDA's acceptance of Medincell's New Drug Application for a once-monthly olanzapine LAI for treating schizophrenia, with a decision expected by the end of the year.